Artelo Biosciences Stock Total Debt
| ARTL Stock | USD 1.05 0.02 1.94% |
Artelo Biosciences fundamentals help investors to digest information that contributes to Artelo Biosciences' financial success or failures. It also enables traders to predict the movement of Artelo Stock. The fundamental analysis module provides a way to measure Artelo Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Artelo Biosciences stock.
Total Debt To Capitalization is expected to rise to 0.01 this year. Artelo | Total Debt |
Artelo Biosciences Company Total Debt Analysis
Artelo Biosciences' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Artelo Biosciences Total Debt | 1.29 M |
Most of Artelo Biosciences' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Artelo Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Artelo Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Artelo Biosciences is extremely important. It helps to project a fair market value of Artelo Stock properly, considering its historical fundamentals such as Total Debt. Since Artelo Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Artelo Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Artelo Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Artelo Total Debt Historical Pattern
Today, most investors in Artelo Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Artelo Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Artelo Biosciences total debt as a starting point in their analysis.
Artelo Biosciences Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Artelo Net Debt
Based on the latest financial disclosure, Artelo Biosciences has a Total Debt of 1.29 M. This is 99.95% lower than that of the Pharmaceuticals sector and 99.6% lower than that of the Health Care industry. The total debt for all United States stocks is 99.98% higher than that of the company.
Artelo Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Artelo Biosciences' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Artelo Biosciences could also be used in its relative valuation, which is a method of valuing Artelo Biosciences by comparing valuation metrics of similar companies.Artelo Biosciences is currently under evaluation in total debt category among its peers.
Artelo Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Artelo Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Artelo Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Artelo Biosciences' value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 17.4 K | Tower Research Capital Llc | 2024-06-30 | 5.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 40.0 | Bank Of America Corp | 2024-06-30 | 26.0 | Rothschild Investment, Llc | 2024-09-30 | 8.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Goss Wealth Management Llc | 2024-06-30 | 0.0 | Citigroup Inc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 |
Artelo Fundamentals
| Return On Equity | -0.89 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | (1.42 M) | ||||
| Shares Outstanding | 3.23 M | ||||
| Shares Owned By Insiders | 0.82 % | ||||
| Shares Owned By Institutions | 0.70 % | ||||
| Number Of Shares Shorted | 21.72 K | ||||
| Price To Earning | 16.31 X | ||||
| Price To Book | 0.52 X | ||||
| EBITDA | (7.44 M) | ||||
| Net Income | (9.29 M) | ||||
| Cash And Equivalents | 21.32 M | ||||
| Cash Per Share | 7.51 X | ||||
| Total Debt | 1.29 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 42.28 X | ||||
| Book Value Per Share | 3.69 X | ||||
| Cash Flow From Operations | (8.21 M) | ||||
| Short Ratio | 1.65 X | ||||
| Earnings Per Share | (2.87) X | ||||
| Target Price | 5.33 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 3.32 M | ||||
| Total Asset | 13.04 M | ||||
| Retained Earnings | (40.31 M) | ||||
| Working Capital | 9.69 M | ||||
| Current Asset | 99.89 M | ||||
| Current Liabilities | 23.67 M | ||||
| Net Asset | 13.04 M |
About Artelo Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Artelo Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Artelo Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Artelo Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Artelo Biosciences Piotroski F Score and Artelo Biosciences Altman Z Score analysis. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.87) | Return On Assets (0.54) | Return On Equity (0.89) |
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.